Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
FDA forces Gilead Sciences' (GILD) to pause enrollment in US leukemia drug trials
August 21, 2023 2:22 PM EDTGilead Sciences (NASDAQ: GILD) announced Monday that the US Food and Drug Administration (FDA) had placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab to treat acute myeloid leukemia (AML).
A clinical hold... More
